| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $8,762,797 | 2 | 4 |
Sells | $89,866,178 | 55 | 96 |
| RA CAPITAL MANAGEMENT, L.P. | director | 2 | $8.76M | 0 | $0 | $8.76M |
| Karydas Daphne | director | 0 | $0 | 4 | $925,537 | $-925,537 |
| Gold Alexander M | director | 0 | $0 | 3 | $1.58M | $-1.58M |
| Warren Eric | Chief Commercial Officer | 0 | $0 | 4 | $3.3M | $-3.3M |
| Levy Adam Scott | CFO and Secretary | 0 | $0 | 2 | $5.71M | $-5.71M |
| Rodman David Malcom | Chief Medical Officer | 0 | $0 | 32 | $13.87M | $-13.87M |
| Congleton Jon | Chief Executive Officer | 0 | $0 | 8 | $18.13M | $-18.13M |
| Slingsby Brian Taylor | 0 | $0 | 2 | $46.36M | $-46.36M |
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 …
Over the last 12 months, insiders at Mineralys Therapeutics, Inc. have bought $8.76M and sold $89.87M worth of Mineralys Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Mineralys Therapeutics, Inc. have bought $30.89M and sold $27.3M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. (director) — $8.76M.
The last purchase of 58,300 shares for transaction amount of $1.41M was made by RA CAPITAL MANAGEMENT, L.P. (director) on 2026‑03‑30.
| 2026-09-30 | Sale | Congleton Jon | Chief Executive Officer | 75,000 0.0862% | $25.46 | $1.91M | -15.20% | |
| 2026-09-22 | Sale | Slingsby Brian Taylor | director | 104,320 0.1217% | $28.81 | $3.01M | -26.50% | |
| 2026-09-21 | Sale | Warren Eric | Chief Commercial Officer | 7,438 0.0085% | $28.12 | $209,136 | -23.56% | |
| 2026-09-15 | Sale | Karydas Daphne | director | 3,000 0.0034% | $28.58 | $85,740 | -23.59% | |
| 2026-08-21 | Sale | Warren Eric | Chief Commercial Officer | 7,437 0.0089% | $25.98 | $193,189 | -2.03% | |
| 2026-08-10 | Sale | Rodman David Malcom | Chief Medical Officer | 2,170 0.0026% | $27.09 | $58,785 | -6.37% | |
| 2026-07-21 | Sale | Warren Eric | Chief Commercial Officer | 7,438 0.011% | $26.87 | $199,885 | -5.98% | |
| 2026-07-17 | Sale | Rodman David Malcom | Chief Medical Officer | 416 0.0006% | $26.53 | $11,036 | -4.21% | |
| 2026-07-15 | Sale | Rodman David Malcom | Chief Medical Officer | 6,349 0.0093% | $26.61 | $168,955 | -4.69% | |
| 2026-07-13 | Sale | Congleton Jon | Chief Executive Officer | 10,700 0.0159% | $27.24 | $291,441 | -5.51% | |
| 2026-07-13 | Sale | Rodman David Malcom | Chief Medical Officer | 14,058 0.0212% | $27.58 | $387,717 | -5.51% | |
| 2026-07-09 | Sale | Rodman David Malcom | Chief Medical Officer | 2,171 0.0034% | $30.30 | $65,781 | -9.74% | |
| 2026-06-30 | Sale | Congleton Jon | Chief Executive Officer | 75,000 0.11% | $26.14 | $1.96M | -2.06% | |
| 2026-06-26 | Sale | Warren Eric | Chief Commercial Officer | 104,124 0.1524% | $25.90 | $2.7M | -0.51% | |
| 2026-06-17 | Sale | Rodman David Malcom | Chief Medical Officer | 4,584 0.0072% | $25.00 | $114,600 | +4.83% | |
| 2026-06-17 | Sale | Karydas Daphne | director | 3,000 0.0047% | $25.00 | $75,000 | +4.83% | |
| 2026-06-15 | Sale | Rodman David Malcom | Chief Medical Officer | 9,890 0.0148% | $23.81 | $235,487 | +10.12% | |
| 2026-06-12 | Sale | Rodman David Malcom | Chief Medical Officer | 6,349 0.0096% | $23.93 | $151,901 | +11.52% | |
| 2026-06-10 | Sale | Rodman David Malcom | Chief Medical Officer | 2,170 0.0034% | $25.00 | $54,250 | +10.23% | |
| 2026-05-18 | Sale | Rodman David Malcom | Chief Medical Officer | 417 0.0007% | $27.55 | $11,488 | -0.19% |
| Slingsby Brian Taylor | director | 7805718 8.8293% | $124.81M | 1 | 3 | +106.96% |
| RA CAPITAL MANAGEMENT, L.P. | director | 5825521 6.5894% | $93.15M | 5 | 0 | +22.98% |
| Congleton Jon | Chief Executive Officer | 528621 0.5979% | $8.45M | 4 | 21 | +24.98% |
| Samsara BioCapital GP, LLC | 10 percent owner | 5674916 6.4191% | $90.74M | 2 | 0 | +46.28% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 3218106 3.6401% | $51.46M | 1 | 0 | <0.0001% |
| AKKARAJU SRINIVAS | director | 588235 0.6654% | $9.41M | 2 | 0 | +48.16% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$831,902,292 | 108 | 9.34% | $1.2B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$530,111,731 | 35 | 8.69% | $1.51B | |
$27,136,525 | 32 | 36.73% | $1.64B |
| Increased Positions | 137 | +69.19% | 23M | +28.83% |
| Decreased Positions | 91 | -45.96% | 14M | -17.44% |
| New Positions | 55 | New | 8M | New |
| Sold Out Positions | 20 | Sold Out | 1M | Sold Out |
| Total Postitions | 244 | +23.23% | 88M | +11.39% |
| Catalys Pacific, Llc | $317,956.00 | 11.27% | 8.9M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $261,531.00 | 9.27% | 7.32M | +1M | +19.14% | 2025-09-30 |
| Samsara Biocapital, Llc | $223,657.00 | 7.93% | 6.26M | +588,235 | +10.37% | 2025-09-30 |
| Blackrock, Inc. | $131,113.00 | 4.65% | 3.67M | +573,854 | +18.52% | 2025-09-30 |
| Vanguard Group Inc | $107,808.00 | 3.82% | 3.02M | +692,550 | +29.77% | 2025-09-30 |
| Caligan Partners Lp | $99,011.00 | 3.51% | 2.77M | +755,302 | +37.44% | 2025-09-30 |
| Capital International Investors | $85,468.00 | 3.03% | 2.39M | -505,624 | -17.44% | 2025-09-30 |
| Suvretta Capital Management, Llc | $76,138.00 | 2.7% | 2.13M | +387,641 | +22.22% | 2025-09-30 |
| Sr One Capital Management, Lp | $75,489.00 | 2.68% | 2.11M | -1M | -32.42% | 2025-09-30 |
| Fmr Llc | $73,965.00 | 2.62% | 2.07M | +2M | +579.35% | 2025-09-30 |